EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)

Objective. To evaluate the effectiveness and tolerance of Etanercept (ETN) therapy in patients with rheumatoid arthritis (RA).Material and Methods. 188 adult patients with severe and moderate RA (average DAS28 score of 6.26±0.89) subcutaneously received 50 mg/wk ETC during 24 wk along with therapy u...

Full description

Bibliographic Details
Main Authors: Anna Olegovna Pchelintseva, E Yu Panasyuk, O F Ryabitseva, V I Mazurov, I G Salikhov, A E Sizikov, O N Ivanova, V N Sorotskaya, O V Semagina, I V Vinogradova, A I Kulikov, L N Denisov, E L Nasonov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2014-02-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/1346
id doaj-83c7c09aadb8426b97878a85851a53c1
record_format Article
spelling doaj-83c7c09aadb8426b97878a85851a53c12021-08-02T09:05:45ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922014-02-015166394510.14412/1995-4484-2013-639-451286EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)Anna Olegovna Pchelintseva0E Yu Panasyuk1O F Ryabitseva2V I Mazurov3I G Salikhov4A E Sizikov5O N Ivanova6V N Sorotskaya7O V Semagina8I V Vinogradova9A I Kulikov10L N Denisov11E L Nasonov12Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaNasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaRegional Clinical Hospital №1 of the Sverdlovsk Region, Yekaterinburg, RussiaSt. Petersburg Medical Academy of Postgraduate Studies, St. Petersburg, RussiaKazan State Medical UniversityInstitute of Clinical Immunology, Siberian Branch, Russian Academy of Medical Sciences, Novosibirsk, RussiaVoronezh Regional Clinical Hospital №1, Voronezh, RussiaTula Regional Hospital, Tula, Russia8Kalinin Samara Regional Clinical Hospital, Samara, RussiaUlyanovsk Regional Clinical Hospital, Ulyanovsk, RussiaRostov State Medical University, Regional Clinical Hospital №2, Rostov-on-Don, RussiaNasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaNasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaObjective. To evaluate the effectiveness and tolerance of Etanercept (ETN) therapy in patients with rheumatoid arthritis (RA).Material and Methods. 188 adult patients with severe and moderate RA (average DAS28 score of 6.26±0.89) subcutaneously received 50 mg/wk ETC during 24 wk along with therapy using disease-modifying antirheumatic drugs (DMARDs). The effectiveness was assessed using the EULAR and ACR20/50/70 criteria, dynamics of HAQ, SDAI, CDAI, ESR, and the C-reactive protein level.Results. By the end of the study, low activity of the disease according to EULAR (DAS28 score ≤ 3.2) was achieved in 31.9% of patients; remission (DAS28 score ≤ 2.6) was achieved in 17% of patients. ACR20/50/70 response was achieved in 72.3; 47.8 and 20.2% of patients, respectively. A decrease in the HAQ index by at least 0.25 points was achieved in 67.5% of patients. The overall EULAR response (moderate and good) was observed in 79.3% of patients; SDAI and CDAI remission/low activity was observed in 52.3 and 52.7% of patients, respectively. Some patients achieved clinical response only by the 25th week of treatment. The originally moderate RA activity and administration of methotrexate are the factors determining higher ETN effectivity in RA patients. The general tolerance of ETN was satisfactory; no uncommon adverse effects were observed.Conclusions. Analysis of the results of ETN therapy for 6 months attests to high effectiveness of this drug. Its advantages include the rapid clinical effect in most patients and good tolerance. ETN can be recommended for treatment of patients with moderate and severe RA when the conventional DMARDs therapy turns out to be insufficiently effective.https://rsp.mediar-press.net/rsp/article/view/1346rheumatoid arthritisetanerceptdas28acr20/50/70sdaicdai
collection DOAJ
language Russian
format Article
sources DOAJ
author Anna Olegovna Pchelintseva
E Yu Panasyuk
O F Ryabitseva
V I Mazurov
I G Salikhov
A E Sizikov
O N Ivanova
V N Sorotskaya
O V Semagina
I V Vinogradova
A I Kulikov
L N Denisov
E L Nasonov
spellingShingle Anna Olegovna Pchelintseva
E Yu Panasyuk
O F Ryabitseva
V I Mazurov
I G Salikhov
A E Sizikov
O N Ivanova
V N Sorotskaya
O V Semagina
I V Vinogradova
A I Kulikov
L N Denisov
E L Nasonov
EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
Научно-практическая ревматология
rheumatoid arthritis
etanercept
das28
acr20/50/70
sdai
cdai
author_facet Anna Olegovna Pchelintseva
E Yu Panasyuk
O F Ryabitseva
V I Mazurov
I G Salikhov
A E Sizikov
O N Ivanova
V N Sorotskaya
O V Semagina
I V Vinogradova
A I Kulikov
L N Denisov
E L Nasonov
author_sort Anna Olegovna Pchelintseva
title EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
title_short EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
title_full EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
title_fullStr EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
title_full_unstemmed EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
title_sort efficacy of etanercept in patients with rheumatoid arthritis (results of the russian multicenter etalon study)
publisher IMA-PRESS LLC
series Научно-практическая ревматология
issn 1995-4484
1995-4492
publishDate 2014-02-01
description Objective. To evaluate the effectiveness and tolerance of Etanercept (ETN) therapy in patients with rheumatoid arthritis (RA).Material and Methods. 188 adult patients with severe and moderate RA (average DAS28 score of 6.26±0.89) subcutaneously received 50 mg/wk ETC during 24 wk along with therapy using disease-modifying antirheumatic drugs (DMARDs). The effectiveness was assessed using the EULAR and ACR20/50/70 criteria, dynamics of HAQ, SDAI, CDAI, ESR, and the C-reactive protein level.Results. By the end of the study, low activity of the disease according to EULAR (DAS28 score ≤ 3.2) was achieved in 31.9% of patients; remission (DAS28 score ≤ 2.6) was achieved in 17% of patients. ACR20/50/70 response was achieved in 72.3; 47.8 and 20.2% of patients, respectively. A decrease in the HAQ index by at least 0.25 points was achieved in 67.5% of patients. The overall EULAR response (moderate and good) was observed in 79.3% of patients; SDAI and CDAI remission/low activity was observed in 52.3 and 52.7% of patients, respectively. Some patients achieved clinical response only by the 25th week of treatment. The originally moderate RA activity and administration of methotrexate are the factors determining higher ETN effectivity in RA patients. The general tolerance of ETN was satisfactory; no uncommon adverse effects were observed.Conclusions. Analysis of the results of ETN therapy for 6 months attests to high effectiveness of this drug. Its advantages include the rapid clinical effect in most patients and good tolerance. ETN can be recommended for treatment of patients with moderate and severe RA when the conventional DMARDs therapy turns out to be insufficiently effective.
topic rheumatoid arthritis
etanercept
das28
acr20/50/70
sdai
cdai
url https://rsp.mediar-press.net/rsp/article/view/1346
work_keys_str_mv AT annaolegovnapchelintseva efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT eyupanasyuk efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT ofryabitseva efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT vimazurov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT igsalikhov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT aesizikov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT onivanova efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT vnsorotskaya efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT ovsemagina efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT ivvinogradova efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT aikulikov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT lndenisov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
AT elnasonov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy
_version_ 1721235871904038912